Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.

Archives of virology - 1 Jan 1994

Gao Q, Gu Z, Salomon H, Nagai K, Parniak M A, Wainberg M A

Abstract excerpt

We have sequentially passaged both laboratory and clinical isolates of the human immunodeficiency virus type 1 (HIV-1) in MT-4 cells in the presence of increasing concentrations of different drugs to derive viral variants that are multiply resistant to various combinations of ddC, ddI, d4T and AZ...

Topics

Antiviral Agents
Cell Line
Cloning, Molecular
Didanosine
Drug Interactions
Drug Resistance, Microbial
HIV-1
Humans
Interferon-alpha
Neutralization Tests
Phenotype
Serial Passage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Stavudine

Zalcitabine

Zidovudine

Source

Identifiers

PMID: 8002779
DOI: 10.1007/BF01538821

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-8002779-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.PMID 8002779Read ↗

Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations.Semantic proximity Read ↗

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.Semantic proximity Read ↗

In vitro selection and characterization of human immunodeficiency virus type 1 resistant to Zidovudine and tenofovir.Semantic proximity Read ↗

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.Semantic proximity Read ↗

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.Semantic proximity Read ↗

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.Semantic proximity Read ↗

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.Semantic proximity Read ↗

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.Semantic proximity Read ↗

3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.Semantic proximity Read ↗

Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.Semantic proximity Read ↗

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.Semantic proximity Read ↗

Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical IsolatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.